Hidden E. coli survive in bladder cells, but existing drug helps antibiotics reach them in lab tests

by Ecole Polytechnique Federale de Lausanne

edited by Gaby Clark, reviewed by Robert Egan

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

Urinary tract infections, or UTIs, are among the most common bacterial infections and are caused mostly by the uropathogenic bacterium Escherichia coli. But even after antibiotic treatment, many patients experience another UTI.

One reason is that the bacterium can enter cells in the bladder's lining (its "epithelium") and hide there, sheltered from both antibiotics and the patient's immune system. These bacteria can later multiply again and cause recurrent UTIs. Repeated antibiotic treatment can then foster antibiotic resistance.

Researchers led by Kathrin Tomasek and John McKinney at the Laboratory of Microbiology and Microtechnology at EPFL, with Christian Pasquali and Mario Romani from OM Pharma, have identified a way to strengthen bladder cells' ability to eliminate these hidden bacteria. Their study, published in PLOS Pathogens, shows that the drug OM-89, marketed as Uro-Vaxom, activates cellular degradation pathways in bladder epithelial cells while also increasing the amount of antibiotic that enters them.

OM-89 has been used for several decades to help prevent recurrent UTIs. It is mainly known for stimulating the immune system, but the new in vitro study reveals a second mechanism of action: a direct effect on the cells lining the bladder.

The lysosome connection

The researchers studied mouse and human bladder epithelial cells using organoid models and differentiated cell cultures. They exposed the cells to OM-89, infected them with different strains of uropathogenic E. coli and treated them with antibiotics. They then tracked bacterial survival, antibiotic uptake and changes in cellular pathways involved in destroying intracellular material.

The results pointed to lysosomes, the acidic compartments inside cells that break down unwanted material. OM-89 increased lysosomal acidification as well as the activity of lysosomal enzymes.

When the researchers blocked lysosomal acidification, OM-89's protective effect was lost. This showed that lysosomal activity is directly involved in reducing bacterial regrowth in recurrent UTIs.

Helping antibiotics reach persistent bacteria

At the same time, OM-89 increased the accumulation of antibiotics inside bladder epithelial cells. When OM-89 and antibiotics were given together in the experimental models, bacterial killing increased and bacterial regrowth after antibiotic removal decreased.

This effect extended across different antibiotic classes and several bacterial strains, including clinical samples from patients.

The researchers also reproduced key effects in both mouse and human bladder epithelial models, while analysis of independent human bladder datasets linked lysosomal activity with immune and antibacterial pathways.

"We found that OM-89 doesn't just stimulate the innate immune system as previously assumed," says Tomasek. "It acts directly on bladder cells, strengthening their degradation pathways so they can destroy hidden bacteria more effectively while also helping antibiotics reach those bacteria—together reducing regrowth of the bacteria after treatment ends."

The findings point toward a host-directed approach to recurrent infection: Rather than targeting bacteria alone, treatment could also reinforce the antimicrobial machinery of the infected tissue itself.

More broadly, the study identifies lysosomal pathways in the bladder epithelium as a potential target for future treatment combinations designed to improve antibiotic outcomes.

Pasquali, senior scientific liaison director at OM Pharma and former head of preclinical research, says, "While the results come from preclinical models and do not change the approved indication or use of Uro-Vaxom, they deepen our understanding of how OM-89 may help strengthen the bladder's natural defenses against recurrent infection and reinforce the scientific foundation supporting its use."

Publication details

Targeted lysosomal activation in bladder epithelium enhances clearance of intracellular uropathogenic Escherichia coli, PLOS Pathogens (2026). DOI: 10.1371/journal.ppat.1014448

Journal information: PLoS Pathogens

Key medical concepts

Recurrent urinary tract infections

Clinical categories

UrologyCommon illnesses & PreventionInfectious diseasesClinical pharmacology Provided by Ecole Polytechnique Federale de Lausanne Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Hidden E. coli survive in bladder cells, but existing drug helps antibiotics reach them in lab tests (2026, September 25) retrieved 25 September 2026 from https://medicalxpress.com/news/2026-09-hidden-coli-survive-bladder-cells.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.